Pegylated liposomal doxorubicin in patients with metastatic triple-negative breast cancer: 8-year experience of a single center

[1] Dent R(2007)Triple-negative breast cancer: clinical features and patterns of recurrence Clin Cancer Res 13 4429-4434

[2] Trudeau M(2011)Stratifying triple-negative breast cancer: which definition(s) to use? Breast Cancer Res 13 105-2121

[3] Pritchard KI(2019)How I treat metastatic triple-negative breast cancer ESMO Open 4 e0005042019-36

[4] Hanna WM(2018)Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer N Engl J Med. 379 2108-66

[5] Kahn HK(2018)Advances in the use of PARP inhibitor therapy for breast cancer Drugs Context. 7 212540-805

[6] Sawka CA(2016)A review of systemic treatment in metastatic triple-negative breast cancer Breast Cancer (Auckl) 10 25-9

[7] Adamo B(2018)Outcomes of systemic therapy for advanced triple-negative breast cancer: a single centre experience Breast 40 60-827

[8] Anders CK(1993)Chemotherapy and survival in advanced breast cancer: the inclusion of doxorubicin in Cooper type regimens Br J Cancer 67 801-75

[9] Caparica R(2012)Comparison of safety and toxicity of liposomal doxorubicin vs. conventional anthracyclines: a meta-analysis Exp Hematol Oncol 1 10-72

[10] Lambertini M(2003)Liposomal anthracyclines in metastatic breast cancer: clinical update Oncologist 8 3-479

[1] Dent R(2007)Triple-negative breast cancer: clinical features and patterns of recurrence Clin Cancer Res 13 4429-4434

[2] Trudeau M(2011)Stratifying triple-negative breast cancer: which definition(s) to use? Breast Cancer Res 13 105-2121

[3] Pritchard KI(2019)How I treat metastatic triple-negative breast cancer ESMO Open 4 e0005042019-36

[4] Hanna WM(2018)Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer N Engl J Med. 379 2108-66

[5] Kahn HK(2018)Advances in the use of PARP inhibitor therapy for breast cancer Drugs Context. 7 212540-805

[6] Sawka CA(2016)A review of systemic treatment in metastatic triple-negative breast cancer Breast Cancer (Auckl) 10 25-9

[7] Adamo B(2018)Outcomes of systemic therapy for advanced triple-negative breast cancer: a single centre experience Breast 40 60-827

[8] Anders CK(1993)Chemotherapy and survival in advanced breast cancer: the inclusion of doxorubicin in Cooper type regimens Br J Cancer 67 801-75

[9] Caparica R(2012)Comparison of safety and toxicity of liposomal doxorubicin vs. conventional anthracyclines: a meta-analysis Exp Hematol Oncol 1 10-72

[10] Lambertini M(2003)Liposomal anthracyclines in metastatic breast cancer: clinical update Oncologist 8 3-479